JP2002527388A5 - - Google Patents

Download PDF

Info

Publication number
JP2002527388A5
JP2002527388A5 JP2000575501A JP2000575501A JP2002527388A5 JP 2002527388 A5 JP2002527388 A5 JP 2002527388A5 JP 2000575501 A JP2000575501 A JP 2000575501A JP 2000575501 A JP2000575501 A JP 2000575501A JP 2002527388 A5 JP2002527388 A5 JP 2002527388A5
Authority
JP
Japan
Prior art keywords
molecular weight
number average
average molecular
hpmc
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000575501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002527388A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1999/007627 external-priority patent/WO2000021525A2/en
Publication of JP2002527388A publication Critical patent/JP2002527388A/ja
Publication of JP2002527388A5 publication Critical patent/JP2002527388A5/ja
Pending legal-status Critical Current

Links

JP2000575501A 1998-10-14 1999-10-12 徐放性医薬組成物および薬学的活性剤の放出の方法 Pending JP2002527388A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17249198A 1998-10-14 1998-10-14
US09/172,491 1998-10-14
PCT/EP1999/007627 WO2000021525A2 (en) 1998-10-14 1999-10-12 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006221194A Division JP4938383B2 (ja) 1998-10-14 2006-08-14 徐放性医薬組成物および薬学的活性剤の放出の方法

Publications (2)

Publication Number Publication Date
JP2002527388A JP2002527388A (ja) 2002-08-27
JP2002527388A5 true JP2002527388A5 (cg-RX-API-DMAC10.html) 2006-10-05

Family

ID=22627919

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000575501A Pending JP2002527388A (ja) 1998-10-14 1999-10-12 徐放性医薬組成物および薬学的活性剤の放出の方法
JP2006221194A Expired - Fee Related JP4938383B2 (ja) 1998-10-14 2006-08-14 徐放性医薬組成物および薬学的活性剤の放出の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006221194A Expired - Fee Related JP4938383B2 (ja) 1998-10-14 2006-08-14 徐放性医薬組成物および薬学的活性剤の放出の方法

Country Status (30)

Country Link
EP (1) EP1121116B1 (cg-RX-API-DMAC10.html)
JP (2) JP2002527388A (cg-RX-API-DMAC10.html)
KR (1) KR100517090B1 (cg-RX-API-DMAC10.html)
CN (1) CN1196481C (cg-RX-API-DMAC10.html)
AR (2) AR020780A1 (cg-RX-API-DMAC10.html)
AT (1) ATE382345T1 (cg-RX-API-DMAC10.html)
AU (1) AU765475B2 (cg-RX-API-DMAC10.html)
BR (1) BR9911648A (cg-RX-API-DMAC10.html)
CA (1) CA2346868C (cg-RX-API-DMAC10.html)
CO (1) CO5140079A1 (cg-RX-API-DMAC10.html)
CY (1) CY1107874T1 (cg-RX-API-DMAC10.html)
DE (1) DE69937891T2 (cg-RX-API-DMAC10.html)
DK (1) DK1121116T3 (cg-RX-API-DMAC10.html)
ES (1) ES2297936T3 (cg-RX-API-DMAC10.html)
HK (1) HK1040920B (cg-RX-API-DMAC10.html)
HU (1) HUP0104268A3 (cg-RX-API-DMAC10.html)
ID (1) ID29350A (cg-RX-API-DMAC10.html)
IL (2) IL142375A0 (cg-RX-API-DMAC10.html)
MY (1) MY121105A (cg-RX-API-DMAC10.html)
NO (1) NO327285B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ511010A (cg-RX-API-DMAC10.html)
PE (1) PE20001110A1 (cg-RX-API-DMAC10.html)
PL (1) PL198850B1 (cg-RX-API-DMAC10.html)
PT (1) PT1121116E (cg-RX-API-DMAC10.html)
RU (1) RU2259826C2 (cg-RX-API-DMAC10.html)
SK (2) SK286595B6 (cg-RX-API-DMAC10.html)
TR (1) TR200101088T2 (cg-RX-API-DMAC10.html)
TW (1) TW577738B (cg-RX-API-DMAC10.html)
WO (1) WO2000021525A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200103001B (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
DE60041281D1 (de) 2000-06-09 2009-02-12 Lek Pharmaceuticals Stabilisiertes arzneimittel und arzneizubereitung
CA2426666A1 (en) * 2000-09-29 2002-04-04 Solvay Pharmaceuticals B.V. Ion-strength independent sustained release pharmaceutical formulation
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
AU2003262059A1 (en) * 2002-09-11 2004-04-30 Takeda Pharmaceutical Company Limited Sustained release preparation
WO2004093883A2 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
WO2007016757A1 (en) * 2005-08-05 2007-02-15 Orbus Pharma Inc. Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
JP2009527577A (ja) * 2006-02-24 2009-07-30 テバ ファーマシューティカル インダストリーズ リミティド フルバスタチンナトリウム医薬組成物
RU2342144C1 (ru) * 2007-04-05 2008-12-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав, обладающий противосудорожным и психотропным действием
RU2356532C2 (ru) * 2007-06-01 2009-05-27 Открытое Акционерное Общество "Отечественные Лекарства" Фармацевтическая композиция проксодолола с контролируемым высвобождением
CN102805739B (zh) * 2012-04-10 2013-08-14 宋芸 氟伐他汀钠缓释包衣滴丸及其制备方法
AU2014205356A1 (en) * 2013-01-09 2015-07-30 Edgemont Pharmaceuticals Llc Controlled release formulations of lorazepam
CN106344535B (zh) * 2016-08-29 2019-09-20 济南康和医药科技有限公司 一种氟伐他汀钠微孔渗透泵控释片及其制备方法
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
CN112955139B (zh) 2018-09-25 2025-04-18 庞塞迪利昂健康特定活动公司 用于制备α-酮戊二酸钙的方法
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
TWI869410B (zh) * 2019-06-10 2025-01-11 愛爾蘭商龐賽德萊昂健康公司 α-酮戊二酸鹽之持續釋放組合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
CA2045428A1 (en) * 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
DK0814782T3 (da) * 1995-12-22 2002-12-16 Nissan Chemical Ind Ltd Farmaceutisk præparat stabiliseret med et basisk middel
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions

Similar Documents

Publication Publication Date Title
TW426528B (en) Controlled release formulations for poorly soluble drugs
US4756911A (en) Controlled release formulation
KR100439614B1 (ko) 가교결합된아밀로즈및하이드록시프로필메틸셀룰로즈계담체를함유하는서방성약제학적정제
EP0465744B1 (en) Formulations for sustained release dressings and their use
US5000962A (en) Long acting diltiazem formulation
TR200101088T2 (tr) Sürekli salınımlı farmasötik kompozisyon ve farmasötik olarak aktif ajanın salınma metodu
CA2191178C (en) Long-lasting release nifedipine preparation
JP2005508331A (ja) 糖尿病の処置のための投与製剤
US4992277A (en) Immediate release diltiazem formulation
JP2002097132A (ja) シロスタゾール有核錠
RU2001111882A (ru) Фармацевтическая композиция с замедленным высвобождением фармацевтичесКи активного вещества и способ высвобождения фармацевтически активного вещества
ES2363390T3 (es) Película monocapa de desintegración rápida para la administración bucal de sustancias activas.
US6994871B2 (en) Once a day antihistamine and decongestant formulation
US20160114043A1 (en) Stabilized Amine-Containing Actives in Oral Film Compositions
TW201031410A (en) Pharmaceutical compositions with superior product performance and patient compliance
CN101087595A (zh) 用于缓释药物的片剂
RU2004118493A (ru) Фармацевтическая суспензия для перорального применения
CZ291258B6 (cs) Orální přípravek, obsahující v matrici bobtnatelné ve vodném prostředí alespoň jednu farmaceutickou účinnou látku
CN110505871B (zh) 用于药物吸收的高负载快速崩解膜
AU2005313262B2 (en) Tablets for the sustained release of indapamide and preparation method thereof
JPS63126825A (ja) 持続放出性ラベタロール錠剤
CN101437545A (zh) 水凝胶片材及其制备方法
JP4552322B2 (ja) 坐剤
CA2259730A1 (en) Sustained release tablets containing bupropion hydrochloride
Arca Cellulose esters and cellulose ether esters for oral drug delivery systems